{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:32:12Z","timestamp":1787016732981,"version":"build-2736575974"},"reference-count":46,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Hearing loss and nephrotoxicity are associated with prolonged treatment duration and higher dosage of amikacin and kanamycin. In our tuberculosis center, we used therapeutic drug monitoring (TDM) targeting preset pharmacokinetic\/pharmacodynamic (PK\/PD) surrogate endpoints in an attempt to maintain efficacy while preventing (oto)toxicity. To evaluate this strategy, we retrospectively evaluated medical charts of tuberculosis (TB) patients treated with amikacin or kanamycin in the period from 2000 to 2012. Patients with culture-confirmed multiresistant or extensively drug-resistant tuberculosis (MDR\/XDR-TB) receiving amikacin or kanamycin as part of their TB treatment for at least 3 days were eligible for inclusion in this retrospective study. Clinical data, including maximum concentration (\n                    <jats:italic>C<\/jats:italic>\n                    <jats:sub>max<\/jats:sub>\n                    ),\n                    <jats:italic>C<\/jats:italic>\n                    <jats:sub>min<\/jats:sub>\n                    , and audiometry data, were extracted from the patients' medical charts. A total of 80 patients met the inclusion criteria. The mean weighted\n                    <jats:italic>C<\/jats:italic>\n                    <jats:sub>max<\/jats:sub>\n                    \/MIC ratios obtained from 57 patients were 31.2 for amikacin and 12.3 for kanamycin. The extent of hearing loss was limited and correlated with the cumulative drug dose per kg of body weight during daily administration. At follow-up, 35 (67.3%) of all patients had successful outcome; there were no relapses. At a median dose of 6.5 mg\/kg, a correlation was found between the dose per kg of body weight during daily dosing and the extent of hearing loss in dB at 8,000 Hz. These findings suggest that the efficacy at this lower dosage is maintained with limited toxicity. A randomized controlled trial should provide final proof of the safety and efficacy of TDM-guided use of aminoglycosides in MDR-TB treatment.\n                  <\/jats:p>","DOI":"10.1128\/aac.01400-16","type":"journal-article","created":{"date-parts":[[2017,1,9]],"date-time":"2017-01-09T21:30:27Z","timestamp":1483997427000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":49,"title":["Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant Tuberculosis"],"prefix":"10.1128","volume":"61","author":[{"given":"R.","family":"van Altena","sequence":"first","affiliation":[{"name":"University of Groningen, University Medical Center Groningen, Tuberculosis Centre Beatrixoord, Haren, The Netherlands"},{"name":"University of Groningen, University Medical Center Groningen, Departments of Pulmonary Diseases and Tuberculosis, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"Dijkstra","sequence":"additional","affiliation":[{"name":"University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. E.","family":"van der Meer","sequence":"additional","affiliation":[{"name":"University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. F.","family":"Borjas Howard","sequence":"additional","affiliation":[{"name":"University of Groningen, University Medical Center Groningen, Department of Internal Medicine, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. G. W.","family":"Kosterink","sequence":"additional","affiliation":[{"name":"University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands"},{"name":"University of Groningen, Department of Pharmacy, Section Pharmacotherapy and Pharmaceutical Care, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"van Soolingen","sequence":"additional","affiliation":[{"name":"National Mycobacteria Reference Laboratory, National Institute of Public Health and the Environment, Bilthoven, The Netherlands"},{"name":"Radboud University Nijmegen Medical Center, Departments of Pulmonary Diseases and Medical Microbiology, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. S.","family":"van der Werf","sequence":"additional","affiliation":[{"name":"University of Groningen, University Medical Center Groningen, Departments of Pulmonary Diseases and Tuberculosis, Groningen, The Netherlands"},{"name":"University of Groningen, University Medical Center Groningen, Department of Internal Medicine, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. W. C.","family":"Alffenaar","sequence":"additional","affiliation":[{"name":"University of Groningen, University Medical Center Groningen, Tuberculosis Centre Beatrixoord, Haren, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.167.4.603"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002849900095"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq374"},{"key":"e_1_3_1_5_2","first-page":"533","article-title":"The early bactericidal activity of amikacin in pulmonary tuberculosis","volume":"5","author":"Donald PR","year":"2001","unstructured":"Donald PR SirgelFAVenterASmitEParkinDPVan de WalBWMitchisonDA. 2001. The early bactericidal activity of amikacin in pulmonary tuberculosis. Int J Tuberc Lung Dis5:533\u2013538.","journal-title":"Int J Tuberc Lung Dis"},{"key":"e_1_3_1_6_2","first-page":"20","volume-title":"Anonymous guidelines for the programmatic management of drug-resistant tuberculosis: emergency update, 2008 ed","author":"World Health Organization","year":"2008","unstructured":"World Health Organization. 2008. Annex 2: weight-based dosing of drugs for adults, p 20. InAnonymous guidelines for the programmatic management of drug-resistant tuberculosis: emergency update, 2008 ed. World Health Organization,Geneva, Switzerland."},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.5.1295"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00851-09"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.9.2971-2973.2003"},{"key":"e_1_3_1_10_2","first-page":"622","article-title":"Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis","volume":"6","author":"de Jager P","year":"2002","unstructured":"de Jager P van AltenaR. 2002. Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis. Int J Tuberc Lung Dis6:622\u2013627.","journal-title":"Int J Tuberc Lung Dis"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6815-7-5"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200262150-00001"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01050-15"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002739"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1472-9792(08)70037-4"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02185842"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/24.3.281"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(02)01476-6"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2004.02114.x"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e31818b6b2f"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/44.2.235"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199212000-00014"},{"key":"e_1_3_1_23_2","volume-title":"NIH publication 09-5410.2013","author":"U.S. Department of Health and Human Services and National Institutes of Health, National Cancer Institute","year":"2010","unstructured":"U.S. Department of Health and Human Services and National Institutes of Health, National Cancer Institute. 2010. Common toxicity criteria (CTC), version 4.03. NIH publication 09-5410.2013. National Institutes of Health,Bethesda, MD."},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00961-16"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00962-16"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1086\/420742"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00184312"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1177\/0194599813501461"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0022215116000062"},{"key":"e_1_3_1_30_2","volume-title":"Anonymous guidelines for the programmatic management of drug-resistant tuberculosis: emergency update, 2008 ed","author":"World Health Organization","year":"2008","unstructured":"World Health Organization. 2008. Anonymous guidelines for the programmatic management of drug-resistant tuberculosis: emergency update, 2008 ed. World Health Organization,Geneva, Switzerland."},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00188313"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-004-1109-5"},{"key":"e_1_3_1_33_2","doi-asserted-by":"publisher","DOI":"10.1086\/321854"},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.4.402"},{"key":"e_1_3_1_35_2","doi-asserted-by":"publisher","DOI":"10.4065\/74.7.730"},{"key":"e_1_3_1_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01117-15"},{"key":"e_1_3_1_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2015.06.008"},{"key":"e_1_3_1_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/40.1.27"},{"key":"e_1_3_1_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.37.10.3179-3186.1999"},{"key":"e_1_3_1_40_2","doi-asserted-by":"publisher","DOI":"10.1086\/424849"},{"key":"e_1_3_1_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00139-10"},{"key":"e_1_3_1_42_2","doi-asserted-by":"publisher","DOI":"10.1086\/651377"},{"key":"e_1_3_1_43_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir658"},{"key":"e_1_3_1_44_2","doi-asserted-by":"publisher","DOI":"10.4155\/bio.14.191"},{"key":"e_1_3_1_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00244-07"},{"key":"e_1_3_1_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.33.6.797"},{"key":"e_1_3_1_47_2","first-page":"640","article-title":"Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis","volume":"9","author":"Laserson KF","year":"2005","unstructured":"Laserson KF ThorpeLELeimaneVWeyerKMitnickCDRiekstinaVZarovskaERichMLFraserHSAlarconECegielskiJPGrzemskaMGuptaREspinalM. 2005. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis9:640\u2013645.","journal-title":"Int J Tuberc Lung Dis"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01400-16","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01400-16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T15:46:55Z","timestamp":1645458415000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01400-16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.1128\/AAC.01400-16"],"URL":"https:\/\/doi.org\/10.1128\/aac.01400-16","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"2016-06-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-12-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-02-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01400-16"}}